MAGEA3 antibody (AA 283-314)

Catalog No. ABIN7873309

The Rabbit Polyclonal anti-MAGEA3 antibody (ABIN7873309) specifically detects MAGEA3 in WB, FACS and IHC (p). The antibody is reactive with Human samples.

Quick Overview for MAGEA3 antibody (AA 283-314) (ABIN7873309)

Target: MAGEA3 (Melanoma Antigen Family A, 3 (MAGEA3))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This MAGEA3 antibody is un-conjugated

Application: Western Blotting (WB), Flow Cytometry (FACS), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Product Details anti-MAGEA3 Antibody

Binding Specificity: AA 283-314

Purpose: MAGE3 Antibody / Melanoma-associated antigen 3

Immunogen: A portion of amino acids 283-314 from the human protein was used as the immunogen for the MAGE3 antibody.

Isotype: Ig Fraction

Application Details

Application Notes: The stated application concentrations are suggested starting points. Titration of the MAGE3 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Restrictions: For Research Use only

Handling

Format: Liquid

Buffer: In 1X PBS, pH 7.4, with 0.09 % sodium azide

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: -20 °C

Storage Comment: Aliquot the MAGE3 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.

Target Details for MAGEA3

Target: MAGEA3 (Melanoma Antigen Family A, 3 (MAGEA3))

Alternative Name: MAGE3

Background: MAGE3, also known as Melanoma-associated antigen 3, is a protein that is commonly expressed in melanoma cells. It plays a crucial role in tumor growth and progression, making it an attractive target for cancer therapy. Research has shown that targeting MAGE3 can effectively inhibit the growth of melanoma cells, leading to the potential development of new treatments for this aggressive form of cancer. One of the most exciting aspects of MAGE3 is its ability to stimulate the immune system to recognize and attack cancer cells. This makes it a promising candidate for immunotherapy, a cutting-edge treatment that harnesses the power of the body's own immune system to fight cancer. By targeting MAGE3, researchers hope to develop more effective and targeted therapies for melanoma patients. Recent studies have highlighted the potential of MAGE3 as a biomarker for predicting the prognosis of melanoma patients. By measuring the levels of MAGE3 in tumor samples, doctors can better tailor treatment plans and improve patient outcomes.

UniProt: P43357